[1] Muñoz L, Stagg HR, Abubakar I Diagnosis and management of latent tuberculosis infection. Cold Spring Harb Perspect Med. 2015;5(11): a017830.
[2] WHO Global tuberculosis report 2018. Available from URL https://www.who.int/tb/publications/global_report/gtbr2018_annex3.pdf?ua=1
[3] Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis [State of the art series. Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]. Int J Tuberc Lung Dis. 2009;13(11):1320-1330.
[4] Castro RA, Ross A, Kamwela L, Reinhard M, Loiseau C, Feldmann J, Borrell S, Trauner A, Gagneux S. The evolution of fluoroquinolone-resistance in Mycobacterium tuberculosis is modulated by the genetic background. bioRXiv. 2019;2019: 659045.
[5] Sharma R, Sharma SK, Singh BK, Mittal A, Kumar P. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India. Indian J Med Res. 2019;149(1): 62-66.
[6] Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One 2015;10(3): e0120470.
[7] Kaur D, Kutum R, Dash D, Brahmachari SK. Data Intensive genome level analysis for identifying novel, non-toxic drug targets for multidrug resistant Mycobacterium tuberculosis. Sci Rep. 2017;7: 46595.
[8] Shah NS, Auld SC, Brust JC, Mathema B, Ismail N, Moodley P, Mlisana K, Allana S, Campbell A, Mthiyane T, Morris N, Mpangase P, van der Meulen H, Omar SV, Brown TS, Narechania A, Shaskina E, Kapwata T, Kreiswirth B, Gandhi NR. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3): 243-253.
[9] Stinson KW, Eisenach K, Kayes S, Matsumoto M, Siddiqi S, Nakashima S. et al. Mycobacteriology Laboratory Manual, global laboratory initiative advancing TB diagnosis. 1sted. April 2014.
[10] Jabeen K, Shakoor S, Malik F, Hasan R (2015) Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010–2014: Implications for disease control. Int J Mycobacteriol. 2015;4:47-48.
[11] Akhtar AM, Arif MA, Kanwal S, Majeed S. Prevalence and drug resistance pattern of MDR TB in retreatment cases of Punjab, Pakistan. J Pak Med Assoc. 2016;66(8): 989-3.
[12] Desai U, Joshi JM. Extrapulmonary drug-resistant tuberculosis at a drug-resistant tuberculosis center, Mumbai: Our experience–Hope in the midst of despair! Lung India 2019;36(1): 3-7.
[13] Sharma AK, Gupta N, Kala DK, Patni T, Dixit R, Verma S, Chandran A. A study on pattern of resistance to second line anti tubercular drugs among multi drug resistant tuberculosis patients. Indian J Tuberc. 2018;65(3): 233-236.
[14] Gao Y, Zhang Z, Deng J, Mansjö M, Ning Z, Li Y, Xu B. Multi-center evaluation of GenoType MTBDRsl line probe assay for rapid detection of pre-XDR and XDR Mycobacterium tuberculosis in China. J Infect. 2018;77(4): 328-334.
[15] Wang Z, Xie T, Mu C, Sun R, Wang C, Zhao H, Ju H. Performance of sequencing in predicting ofloxacin resistance in Mycobacterium tuberculosis from positive Bactec MGIT 960 cultures. Ann Clin Lab Sci. 2018;48(1): 69-74.
[16] Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJM, Hossain MA, Van Deun A. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother. 2015;71(2): 314-323.
[17] Kamal SMM, Hossain A, Sultana S, Begum V, Haque N, Ahmed J, Chowdhury RA. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int. J Tuberc Lung Dis. 2015;19(2): 151-156.
[18] Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother. 2009;53(10): 4498-4500.
[19] Singhal R, Reynolds PR, Marola JL, Epperson LE, Arora J, Sarin R, Myneedu VP, Strong M, Salfinger M. Sequence analysis of fluoroquinolone resistance-associated genes gyrA and gyrB in clinical Mycobacterium tuberculosis isolates from patients suspected of having multidrug-resistant tuberculosis in New Delhi, India. J Clin Microbiol. 2016;54(9): 2298-2305.
[20] Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect. 2017;23(3):154-160.
[21] Giannoni F, Iona E, Sementilli F, Brunori L, Pardini M., Migliori B, Orefici G, Fattorini L. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49(7):2928-2933.
[22] Juarez-Eusebio DM, Munro-Rojas D, Muñiz-Salazar R, Laniado-Laborín R, Martinez-Guarneros JA, Flores-López CA, Zenteno-Cuevas R. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico. Infect Genet Evol. 2017;55: 384-391.
[23] Ali A, Hasan R, Jabeen K, Jabee N, Qadeer E, Hasan Z. Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan. Antimicrob Agents chemother. 2011;55(12):5654-5659.